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Introduction {#jgh312263-sec-0005}
============

Stone removal by endoscopic retrograde cholangiopancreatography (ERCP) is an effective strategy for common bile duct (CBD) stones.[1](#jgh312263-bib-0001){ref-type="ref"}, [2](#jgh312263-bib-0002){ref-type="ref"}, [3](#jgh312263-bib-0003){ref-type="ref"} Endoscopic stone removal is completed following endoscopic sphincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) using a basket or balloon in 85--90% of patients with CBD stones. For large CBD stones, mechanical lithotripsy has a high success rate for stone removal.[1](#jgh312263-bib-0001){ref-type="ref"} Endoscopic papillary large balloon dilation (EPLBD) is effective for the removal of multiple and large CBD stones that are difficult to remove by EPBD or EST alone.[4](#jgh312263-bib-0004){ref-type="ref"}

In the Tokyo guidelines 2018, papillary treatments, such as EST or EPBD, and subsequent single‐stage stone removal are acceptable in patients with mild‐to‐moderate acute cholangitis.[5](#jgh312263-bib-0005){ref-type="ref"} Therefore, single‐stage endoscopic stone removal is often performed for choledocholithiasis in clinical practice.

However, ERCP is a high‐risk procedure with complications, such as cholangitis, bleeding, perforation, and pancreatitis. Of these complications, post‐ERCP pancreatitis (PEP) is the most common and serious complication, which can be lethal.[6](#jgh312263-bib-0006){ref-type="ref"} Although endoscopic stone removal requires papillary treatment, including EST, EPBD, or EPLBD, these papillary treatments are risk factors of PEP.[4](#jgh312263-bib-0004){ref-type="ref"}, [7](#jgh312263-bib-0007){ref-type="ref"} One concern is that the risk of PEP may increase when single‐stage endoscopic stone removal is performed in addition to papillary treatment at the same time because of exacerbation of papilla trauma, especially in cases of prolonged biliary cannulation. On the other hand, single‐stage endoscopic stone removal has some advantages, such as shortened hospital stays and reduced ERCP attempts, which lead to reduced medical costs.[8](#jgh312263-bib-0008){ref-type="ref"} However, there are few reports on the incidence of PEP in single‐stage endoscopic stone removal in patients with native papilla.

The aim of this study was to compare the overall incidence of PEP between single‐stage and two‐stage stone removal procedures and the incidence of PEP between these two procedures based on cannulation time for choledocholithiasis, with no inflammation or mild‐to‐moderate acute cholangitis, in patients with native papilla.

Materials and methods {#jgh312263-sec-0006}
=====================

*Patient selection and data source* {#jgh312263-sec-0007}
-----------------------------------

Using medical records between April 2012 and March 2018, we identified 1244 patients who had CBD stone diseases with native papilla and normal gastrointestinal tract or Billroth I gastrectomy and who underwent papillary treatment, including EST, EPBD, and EPLBD, at Kumamoto Chuo Hospital, Kumamoto City Hospital, and Saiseikai Kumamoto Hospital. Of these patients, we excluded those who had biliary pancreatitis (*n* = 113), severe acute cholangitis (*n* = 81), undetected CBD stones during ERCP (*n* = 101), unsuccessful stone removal (*n* = 37), and unsuccessful deep cannulation (*n* = 15). Finally, 897 patients with mild‐to‐moderate acute cholangitis, obstructive jaundice, elevated liver test results, and asymptomatic CBD stones were analyzed. Informed consent was obtained from all the patients. The Institutional Review Boards of each institution approved this study, and it was performed in accordance with the Declaration of Helsinki.

*Diagnostic procedure* {#jgh312263-sec-0008}
----------------------

In this study, one or more imaging examinations, including computed tomography, magnetic resonance cholangiopancreatography, ultrasonography, endoscopic ultrasonography, and cholangiography from percutaneous transhepatic gallbladder drainage tube, were performed to diagnose the presence of CBD stones in all patients. In patients with undetected CBD stone by imaging, we diagnosed CBD stones on the basis of clinical diagnosis, such as abdominal pain and/or elevated liver test results and/or dilated CBD. For diagnosis and grading of acute cholangitis, we used the Tokyo guidelines 2018.[9](#jgh312263-bib-0009){ref-type="ref"}

*Therapeutic procedure* {#jgh312263-sec-0009}
-----------------------

### *Premedication, scopes, and devices for stone removal* {#jgh312263-sec-0010}

Midazolam and pethidine hydrochloride were used for sedation, and scopolamine butylbromide, or glucagon was used for duodenal relaxation. We used side‐viewing duodenoscopy (Olympus JF‐260, TJF‐260V; Olympus Medical Systems, Tokyo, Japan) in all the patients. A basket and/or a balloon catheter and/or a mechanical lithotriptor were used to remove CBD stones.

### *Endoscopists* {#jgh312263-sec-0011}

Of a total of 29 different endoscopists, 11 were trainees, defined as endoscopists who had experienced \<200 ERCP procedures or who could complete ERCP that corresponded to grade 1 based on the grading scale of the ERCP core curriculum.[10](#jgh312263-bib-0010){ref-type="ref"}

*Definitions* {#jgh312263-sec-0012}
-------------

### *Single‐stage and two‐stage endoscopic stone removal* {#jgh312263-sec-0013}

Single‐stage endoscopic stone removal was defined as CBD stone removal in addition to papillary treatment, including EST, EPBD, or EPLBD at the same time. Two‐stage endoscopic stone removal was defined as CBD stone removal a few days after papillary treatment and subsequent biliary drainage.

### *Difficult deep cannulation* {#jgh312263-sec-0014}

We defined difficult cannulation as cases requiring \>10 min for deep cannulation in this study because a cannulation attempt requiring \>10 min has been previously found to be a definite risk factor of PEP.[7](#jgh312263-bib-0007){ref-type="ref"}

### *Post‐ERCP pancreatitis* {#jgh312263-sec-0015}

PEP was diagnosed and graded on the basis of the consensus criteria by Cotton *et al*.[11](#jgh312263-bib-0011){ref-type="ref"} The diagnostic criteria of PEP were new or worsening abdominal pain with serum amylase \>3 times the normal at 24 h after ERCP requiring new or prolonged hospitalization of ≥1 night. Mild PEP was defined as cases requiring hospitalization for 2--3 days, and moderate PEP was defined as cases requiring hospitalization for 4--10 days. Severe PEP was defined as cases requiring hospitalization for \>10 days or percutaneous drainage or surgery.

*Outcomes* {#jgh312263-sec-0016}
----------

Primary outcomes of this study were the overall incidence of PEP for single‐stage stone removal procedure and the incidence of PEP for this procedure based on cannulation time. Secondary outcomes were the mean number of ERCP sessions for stone clearance and mean length of hospital stay.

*Statistical analysis* {#jgh312263-sec-0017}
----------------------

The patients\' characteristics and clinical risk factors of PEP were compared between the single‐stage stone removal group and two‐stage stone removal group by using chi‐square tests, Fisher\'s exact tests, or *t*‐tests as appropriate. The association between single‐stage stone removal and the overall incidence of PEP was examined by performing one‐to‐one propensity score matching with a caliper and a standard deviation of 0.2 and regression adjustment by propensity score to adjust for potential confounders. Each characteristic variable of the patient and the clinical risk factors of PEP shown in Tables [1](#jgh312263-tbl-0001){ref-type="table"} and [2](#jgh312263-tbl-0002){ref-type="table"} were used to construct propensity scores.[12](#jgh312263-bib-0012){ref-type="ref"} C‐statistics were calculated to evaluate the goodness of fit. We used standardized mean difference (SMD), which is not influenced by sample size, to check the balance of matched samples between single‐ and two‐stage stone removal groups. Propensity‐matched samples with SMD \<0.10 is desirable.[13](#jgh312263-bib-0013){ref-type="ref"} In this study, SMD in almost all factors shown in Tables [1](#jgh312263-tbl-0001){ref-type="table"} and [2](#jgh312263-tbl-0002){ref-type="table"} was \<0.10, and SMD in only a factor of pancreatic injection was 0.105. Regression adjustment by propensity score was used to examine the association between the incidence of PEP and single‐stage stone removal procedure based on the cannulation time. In this analysis, we constructed propensity scores for each of the four groups of single‐stage stone removal procedure after the cannulation times of ≤5, \>5 to ≤10, \>10 to ≤15, and \>15 min. Thereafter, a logistic regression analysis was performed in each of the four groups, where the incidence of PEP took place of the outcome, and the binary variable of the single‐ and two‐stage stone removal procedure groups and the estimated propensity scores took the place of explanatory variables. A *P* value \<0.05 was used as the threshold for statistical significance. JMP® Pro 13 (SAS Institute, Cary, NC, USA) and R version 3.5.1 (<http://www.r-project.org>) were used to perform all the statistical analyses.

###### 

Characteristics of all patients and matched patients in the single‐stage and two‐stage stone removal groups

                                                                                 All patients (*n* = 897)          Matched patients (*n* = 468)                                                             
  ----------------------------------------------------------------------------- -------------------------- ------ ------------------------------ ------ --------- ------------- ------ ------------- ------ ------
  Age (mean \[SD\], years)                                                             70.6 (14.2)                         74.5 (13.7)                   \<0.001   71.9 (13.8)          70.7 (15.0)          0.36
  Gender (female)                                                                          144              46.9               267                45.3    0.69         106       45.3       114       48.7   0.52
  Indication for ERCP                                                                                                                                    \<0.001                                             0.89
  Mild cholangitis                                                                          94              30.6               215                36.4                 85        36.3       86        36.8  
  Moderate cholangitis                                                                      36              11.7               170                28.8                 35        15.0       33        14.1  
  Obstructive jaundice and/or elevated liver test results without cholangitis              108              35.2               137                23.3                 73        31.2       79        33.8  
  Asymptomatic CBD stones                                                                   69              22.5                68                11.5                 41        17.5       36        15.4  
  Comorbidities                                                                                                                                           0.19                                               0.99
  Acute pancreatitis                                                                        3               1.0                 1                 0.2                   1        0.4         1        0.4   
  Chronic pancreatitis                                                                      0                0                  1                 0.2                   0         0          0         0    
  Hemodialysis                                                                              3               1.0                 7                 1.2                   3        1.3         4        1.7   
  Cardiovascular disease                                                                    28              9.1                 76                12.9                 26        11.1       22        9.4   
  Cerebrovascular disease                                                                   15              4.9                 47                8.0                  14        6.0        12        5.1   
  Liver cirrhosis                                                                           2               0.7                 8                 1.4                   2        0.9         3        1.3   
  Diabetes mellitus                                                                         38              12.4                71                12.0                 29        12.4       31        13.2  
  ≥2 comorbidities                                                                          33              10.7                60                10.2                 24        10.3       23        9.8   
  Periampullary diverticulum                                                                92              30.0               153                25.9    0.23         68        29.1       65        27.8   0.84
  Multiple stones                                                                          122              39.7               225                38.1    0.69         91        38.9       87        37.2   0.78
  Large stone (\>10 mm)                                                                     33              10.7               113                19.2    0.002        29        12.4       30        12.8   1.0
  Gallbladder stones                                                                       217              70.7               343                58.1   \<0.001       156       66.7       163       69.7   0.55
  Postcholecystectomy                                                                       27              8.8                 73                12.4    0.13         22        9.4        19        8.1    0.74
  Performance status (3 or 4)                                                               40              13.0                91                15.4    0.39         37        15.8       32        13.7   0.60

CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography.

###### 

Clinical risk factors of post‐ERCP pancreatitis in all and matched patients between the single‐stage and two‐stage stone removal groups

                                           All patients          Matched patients                                                            
  --------------------------------------- -------------- ------ ------------------ ------ --------- ------------ ------ ------------- ------ ------
  Normal serum bilirubin                       153        49.8         193          32.7   \<0.001      105       44.9       98        41.9   0.58
  Nondilated common bile duct                  184        59.9         263          44.6   \<0.001      127       54.3       131       56.0   0.78
  Pharmacological prevention                   161        52.4         272          46.1    0.083       117       50.0       113       48.3   0.78
  Trainee endoscopist                           63        20.5          98          16.6    0.17         44       18.8       40        17.1   0.72
  Pancreatic injections                        115        37.5         302          51.2   \<0.001       88       37.6       100       42.7   0.30
  PGW‐assist cannulation                        31        10.1         127          21.5   \<0.001       26       11.1       33        14.1   0.40
  Precut sphincterotomy                         5         1.6           36          6.1     0.004        5        2.1         6        2.6    1.0
  EPBD or EPLBD                                 42        13.7          60          10.2    0.14         26       11.1       27        11.5   1.0
  Cannulation time                                                                          0.043                                             0.84
  ≤5 min                                       175        57.0         314          53.2                140       59.8       131       56.0  
  \>5 to ≤10 min                                63        20.5          96          16.3                 43       18.4       46        19.7  
  \>10 to ≤15 min                               28        9.1           61          10.3                 20       8.5        24        10.3  
  \>15 min                                      41        13.4         119          20.2                 31       13.2       33        14.1  
  Absence of pancreatic stent placement        296        96.4         498          84.4   \<0.001      224       95.7       221       94.4   0.67
  Use of ≥2 devices for stone removal          136        44.3         344          58.3   \<0.001      112       47.9       105       44.9   0.58
  Procedure time (SD)                      29.5 (15.4)             25.9 (15.3)             \<0.001   27.5(13.7)          28.1 (17.9)          0.70

EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; PGW, pancreatic guide wire.

Results {#jgh312263-sec-0018}
=======

*Patients\' demographics and clinical risk factors* {#jgh312263-sec-0019}
---------------------------------------------------

Patients\' demographics and clinical risk factors of all patients and propensity‐matched patients who underwent single‐stage and two‐stage stone removal are shown in Tables [1](#jgh312263-tbl-0001){ref-type="table"} and [2](#jgh312263-tbl-0002){ref-type="table"}, respectively. Pharmacological prevention included the use of a protease inhibitor and rectal nonsteroidal anti‐inflammatory drugs (NSAIDs). There was no significant difference in the incidence of PEP between a protease inhibitor and rectal NSAIDs in all patients and matched patients (*P* = 0.55 and *P* = 1.0, respectively).

*Successful cannulation rates* {#jgh312263-sec-0020}
------------------------------

The successful cannulation rate in patients diagnosed as having CBD stone diseases, excluding biliary pancreatitis and severe acute cholangitis, was 1035 of 1050 (98.6%). Fifteen patients with unsuccessful cannulation were excluded in the present study.

*Rate of complete stone clearance* {#jgh312263-sec-0021}
----------------------------------

The rate of CBD stones detected by ERCP in patients diagnosed as having CBD stones on the basis of imaging or clinical findings, excluding biliary pancreatitis, severe acute cholangitis, and unsuccessful cannulation, was 934 of 1035 (90.2%). The 101 patients in whom CBD stones were not detected by ERCP were excluded from this study. The rate of complete stone clearance was 897 of 934 (96.0%). In addition, the 37 patients with unsuccessful stone removal were excluded.

*Incidence rates of PEP* {#jgh312263-sec-0022}
------------------------

Table [3](#jgh312263-tbl-0003){ref-type="table"} presents the incidences of PEP in single‐stage stone removal and two‐stage stone removal. In all patients, of 307 patients with single‐stage stone removal, PEP occurred in 20 (6.5%) patients, and of 590 patients with two‐stage stone removal, PEP occurred in 21 (3.6%) patients. There was no significant difference in the incidence of PEP between the single‐stage and two‐stage stone removal groups (*P* = 0.062). In propensity‐matched patients with 234 pairs, the incidences of PEP were 15 (6.4%) patients in the single‐stage stone removal group and 6 (2.6%) patients in the two‐stage stone removal group. There were no significant differences in the incidence of PEP in the matched patients between the two groups (*P* = 0.072; Table [3](#jgh312263-tbl-0003){ref-type="table"}).

###### 

Incidences of post‐ERCP pancreatitis in all patients and matched patients

                                All patients          Matched patients                                           
  ---------------------------- -------------- ------ ------------------ ------ ------- ----- ------ ----- ------ -------
  Post‐ERCP pancreatitis (+)         20        6.5           21          3.6    0.062   15    6.4     6    2.6    0.072
  Post‐ERCP pancreatitis (−)        287        93.5         569          96.4           219   93.6   228   97.4  

ERCP, endoscopic retrograde cholangiopancreatography.

*Effect of single‐stage stone removal for the overall incidence of PEP after adjusting for confounding factors* {#jgh312263-sec-0023}
---------------------------------------------------------------------------------------------------------------

We performed propensity score analysis, including propensity‐matched analysis and regression adjustment by propensity score, to adjust for confounding factors. Table [4](#jgh312263-tbl-0004){ref-type="table"} shows the results of the propensity score analysis. Single‐stage stone removal was not a significant risk factor in propensity‐matched analysis and regression adjustment for confounding factors by propensity score (*P* = 0.072, 95% CI = 0.99--6.8 and *P* = 0.094, 95% CI = 0.90--3.8, respectively).

###### 

Effect of single‐stage stone removal for post‐ERCP pancreatitis after adjusting for confounding factors

  Statistical analysis method                  *P* value    95% CI
  ------------------------------------------- ----------- -----------
  Propensity‐matched analysis                    0.072     0.99--6.8
  Regression adjustment by propensity score      0.094     0.90--3.8

ERCP, endoscopic retrograde cholangiopancreatography.

*Cannulation time‐based comparison of the association between the incidence of PEP and single‐ and two‐stage stone removal procedures* {#jgh312263-sec-0024}
--------------------------------------------------------------------------------------------------------------------------------------

In all and propensity‐matched patients, the single‐stage stone removal procedure after cannulation times of ≤5, \>5 to ≤10, and \> 10 to ≤15 min did not increase the incidence of PEP compared to the two‐stage stone removal procedure. However, in all patients and matched patients with cannulation times \>15 min, the incidence of PEP was significantly higher in the single‐stage stone removal group than in the two‐stage stone removal group \[all patients; 10/41 (24.4%) *vs* 10/119 (8.4%), *P* = 0.013, matched patients; 10/31 (32.3%) *vs* 1/33 (3.0%), *P* = 0.011; Table [5](#jgh312263-tbl-0005){ref-type="table"}\]. The single‐stage stone removal procedure with cannulation times above 15 min was a significant risk factor of PEP as estimated by regression adjustment by propensity score (*P* = 0.014, 95% CI = 1.4--19.4, odds ratio = 5.2; Table [6](#jgh312263-tbl-0006){ref-type="table"}).

###### 

Cannulation time‐based comparison of the association between the incidence of post‐ERCP pancreatitis and single‐ and two‐stage stone removal procedures

                                                    Incidence of post‐ERCP pancreatitis                                     
  ------------------------------------------------ ------------------------------------- -------------- ---- -------------- -------
  All patients                                                                                                              
  Cannulation time ≤ 5 min (*n* = 489)                               5                    2.9 (5/175)    4    1.3 (4/314)    0.29
  5 min \< Cannulation time ≤ 10 min (*n* = 159)                     3                     4.8 (3/63)    4     4.2 (4/96)     1.0
  10 min \< Cannulation time ≤ 15 min (*n* = 89)                     2                     7.1 (2/28)    3     4.9 (3/61)    0.65
  Cannulation time \> 15 min (*n* = 160)                            10                    24.4 (10/41)   10   8.4 (10/119)   0.013
  Matched patients                                                                                                          
  Cannulation time ≤ 5 min (*n* = 271)                               3                    2.1 (3/140)    4    3.1 (4/131)    0.72
  5 min \< Cannulation time ≤ 10 min (*n* = 89)                      1                     2.3 (1/43)    1     2.2 (1/46)     1.0
  10 min \< Cannulation time ≤ 15 min (*n* = 44)                     1                     5.0 (1/20)    0      0 (0/24)     0.45
  Cannulation time \> 15 min (*n* = 64)                             10                    32.3 (10/31)   1     3.0 (1/33)    0.011

ERCP, endoscopic retrograde cholangiopancreatography.

###### 

Effect of single‐stage stone removal procedure compared with the two‐stage one based on the cannulation time for post‐ERCP pancreatitis after regression adjustment by propensity score

                                                                                     *P* value     95% CI     Odds ratio
  --------------------------------------------------------------------------------- ----------- ------------ ------------
  Single‐stage stone removal procedure after cannulation time of ≤5 min                0.89      0.24--5.1       1.1
  Single‐stage stone removal procedure after cannulation time of \>5 to ≤ 10 min       0.86      0.17--8.4       1.2
  Single‐stage stone removal procedure after cannulation time of \>10 to ≤ 15 min      0.66      0.10--39.1      2.0
  Single‐stage stone removal procedure after cannulation time \> 15 min                0.014     1.4--19.4       5.2

ERCP, endoscopic retrograde cholangiopancreatography.

*Efficacy of single‐stage stone removal* {#jgh312263-sec-0025}
----------------------------------------

Table [7](#jgh312263-tbl-0007){ref-type="table"} shows the number of ERCP attempts for stone clearance and length of hospital stays of matched patients in the single‐ and two‐stage stone removal groups. The mean number of ERCP attempts of complete stone removal was significantly smaller (1.5 attempts *vs* 2.2 attempts, respectively; *P* \< 0.001), and the mean length of hospital stays was significantly shorter in the single‐stage stone removal group than in the two‐stage stone removal group (8.6 days *vs* 10.9 days, respectively; *P* \< 0.001).

###### 

ERCP sessions for stone clearance and hospital stays of matched patients in the single‐stage and two‐stage stone removal groups

                                        Single‐stage group   Two‐stage group   *P* value
  ------------------------------------ -------------------- ----------------- -----------
  ERCP sessions (mean \[SD\])               1.5 (0.64)         2.2 (0.48)       \<0.001
  Hospital stays (mean \[SD\], days)        8.6 (5.3)          10.9 (5.6)       \<0.001

ERCP, endoscopic retrograde cholangiopancreatography.

Discussion {#jgh312263-sec-0026}
==========

This study investigated the incidence of PEP by single‐stage endoscopic stone removal for choledocholithiasis, including asymptomatic CBD stones, elevated liver test results and/or obstructive jaundice without cholangitis, and mild‐to‐moderate acute cholangitis. We conducted a propensity‐matched analysis and regression adjustment by propensity score to adjust for potential confounding factors of PEP. Although single‐stage endoscopic stone removal was not a significant risk factor for PEP overall, this procedure after cannulation times \>15 min was a significant risk factor of PEP.

PEP is the most common and serious complication associated with ERCP and can be lethal. A recent systematic review that analyzed 108 randomized controlled studies stated that the PEP incidence was 9.7%, and the PEP mortality was 0.15%.[14](#jgh312263-bib-0014){ref-type="ref"} The risk factor of PEP is divided into patient‐related and procedure‐related risk factors in the available guidelines. Single‐stage endoscopic stone removal is not listed as a risk factor of PEP in the guidelines.[7](#jgh312263-bib-0007){ref-type="ref"}, [15](#jgh312263-bib-0015){ref-type="ref"} However, there are few reports that state whether single‐stage endoscopic stone removal is a risk factor of PEP or not in patients with native papilla.

In the Tokyo guidelines 2018, papillary treatments, such as EST and EPBD, and subsequent single‐stage stone removal are acceptable in patients with mild‐to‐moderate acute cholangitis.[5](#jgh312263-bib-0005){ref-type="ref"} Therefore, single‐stage endoscopic stone removal is often performed for CBD stones in clinical practice. However, we hypothesized that single‐stage stone removal may be a risk factor of PEP because single‐stage endoscopic stone removal in addition to papillary treatment at the same time may exacerbate papillary trauma and lead to pancreatic flow blockage, which is considered to be the cause of PEP.[15](#jgh312263-bib-0015){ref-type="ref"}

A retrospective study that included 345 patients with native papilla showed that single‐stage endoscopic stone removal was not a significant risk factor of PEP in multivariate analysis.[8](#jgh312263-bib-0008){ref-type="ref"} However, the aim of the previous study was to examine the overall incidence of complications associated with single‐stage endoscopic stone removal, and the study included biliary pancreatitis. Another study in 50 patients with mild‐to‐moderate acute cholangitis reported that the incidence of ERCP‐related complications was 10% (5/50) and the incidence of PEP was 2% (1/50) after single‐stage endoscopic stone removal procedure.[16](#jgh312263-bib-0016){ref-type="ref"} However, these past reports were not focused on the incidence of PEP arising from single‐stage stone removal.

The present study showed that single‐stage stone removal was not a significant risk factor of PEP after adjusting for potential confounding factors overall. However, in patients who underwent the single‐stage stone removal procedure after cannulation times of \>15 min, the incidence of PEP was significantly higher than that in the two‐stage stone removal group. Stone removal subsequent biliary cannulation attempt durations of \>15 min can be an invasive procedure that causes exacerbation of papilla trauma sufficient to block pancreatic flow and lead to PEP. The results of the present study suggested that single‐stage stone removal is suitable for patients with cannulation times of ≤15 min.

In this study, the single‐stage stone removal procedure after cannulation time ≤ 15 min was performed in more than 80% of enrolled patients, and this procedure after cannulation time \> 15 min was performed in less than 20% of enrolled patients in both all and matched patient groups. There was no statistical difference in the overall incidence of PEP between single‐ and two‐stage stone removal procedures in all and matched patients. This is because the proportion of the single‐stage stone removal procedure after cannulation time ≤ 15 min was greater than that of single‐stage stone removal after cannulation time \> 15 min in both all and matched patients.

There are past reports on the devices used to remove CBD stones. Balloon catheters and basket catheters are widely available. Mechanical lithotripsy is performed for cases of difficult stones in which standard stone removal using a balloon or basket catheter cannot be achieved.[17](#jgh312263-bib-0017){ref-type="ref"} A multicenter prospective randomized trial demonstrated that the rate of complete stone clearance with a single catheter for CBD stones of ≤10 mm was higher in the balloon catheter group than in the basket catheter group. One study found that there was no significant difference in the rates of PEP and complete stone clearance in one ERCP session between the balloon catheter group and basket catheter group.[18](#jgh312263-bib-0018){ref-type="ref"} Mechanical lithotripsy achieves successful stone clearance in 80--90% of patients with difficult CBD stones. A prospective study showed that use of a mechanical lithotriptor did not increase the incidence of PEP relative to that occurring after standard sphincterotomy.[19](#jgh312263-bib-0019){ref-type="ref"}

The advantages of single‐stage stone removal compared with two‐stage stone removal were found to be the expectation of fewer ERCP attempts and shortened hospital stays, which would lead to reduced medical costs. In the propensity‐matched patients in this study, there were significantly fewer ERCP attempts for stone clearance and hospital stays in the single‐stage stone removal group than in the two‐stage stone removal group.

There were several limitations in the present study. First, although we performed propensity score analysis, including propensity‐matched analysis and regression adjustment by propensity score to adjust for potential confounding factors, some unmeasured confounding factors may not have been excluded. Second, because Kumamoto City Hospital suffered from tremendous damage due to the Kumamoto earthquake in April 2016 and ERCP could not be performed afterward, the data obtained from Kumamoto City Hospital was for 4 years only (April 2012 to April 2016).

In conclusion, we used propensity score analysis to examine the incidence of PEP in single‐stage stone removal for choledocholithiasis with no inflammation or mild‐to‐moderate acute cholangitis. Overall, single‐stage stone removal was not a significant risk factor for PEP. However, single‐stage stone removal procedure after a long cannulation times of \>15 min was a significant risk factor of PEP. Single‐stage stone removal may be a safe procedure with respect to PEP in cases with cannulation times of ≤15 min.
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